DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hemophilia B market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hemophilia B Market Forecast

Some of the key facts of the Hemophilia B Market Report: 

• The Hemophilia B market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there were 10,739 people with haemophilia B overall in 2020, and by 2032, that number was predicted to increase
• About 75% of patients with haemophilia B have moderate or severe cases. In 2020, there were around 8,054 moderate and severe cases of haemophilia B in the 7MM
• France had the highest prevalence of haemophilia B among the five European nations in 2020, followed by the United Kingdom
• Key Hemophilia B Companies: Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure, Novo Nordisk, Freeline Therapeutics, ApcinteX, Bioverativ Therapeutics, Grifols Biologicals, Novo Nordisk A/S, Medexus Pharma, and others
• Key Hemophilia B Therapies: Marstacimab(PF-06741086), SPK-9001, Fitusiran, AMT-061, Concizumab, FLT180a, SerpinPC, rFIXFc, BeneFIX, Nonacog beta pegol, APVO101, rFIX-R, and others
• The Hemophilia B epidemiology based on severity analyzed that moderate and severe accounts for ~75% of the Hemophilia B patient pool
• The Hemophilia B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hemophilia B pipeline products will significantly revolutionize the Hemophilia B market dynamics.

Hemophilia B Overview

People with haemophilia B, a rare inherited bleeding illness, have low quantities of the blood protein factor IX. The quantity of factor IX (FIX) in a person's blood determines the severity of their haemophilia.

Get a Free sample for the Hemophilia B Market Report 

https://www.delveinsight.com/report-store/hemophilia-b-market

Hemophilia B Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hemophilia B Epidemiology Segmentation:

The Hemophilia B market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Hemophilia B
• Prevalent Cases of Hemophilia B by severity
• Gender-specific Prevalence of Hemophilia B
• Diagnosed Cases of Episodic and Chronic Hemophilia B

Download the report to understand which factors are driving Hemophilia B epidemiology trends @ Hemophilia B Epidemiology Forecast

Hemophilia B Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia B market or expected to get launched during the study period. The analysis covers Hemophilia B market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hemophilia B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hemophilia B Therapies and Key Companies

• Marstacimab(PF-06741086): Pfizer
• SPK-9001: Pfizer/Spark Therapeutics
• Fitusiran: Sanofi/ Alnylam Pharmaceuticals
• AMT-061: CSL Behring/ uniQure
• Concizumab: Novo Nordisk
• FLT180a: FreelineTherapeutics
• SerpinPC: ApcinteX
• rFIXFc: Bioverativ Therapeutics
• BeneFIX: Grifols Biologicals
• Nonacog beta pegol: Novo Nordisk A/S
• APVO101: Medexus Pharma
• rFIX-R: Pfizer

Discover more about therapies set to grab major Hemophilia B market share @ Hemophilia B Treatment Market

Hemophilia B Market Drivers

• Popularity of Gene Therapy
• Development of Novel Treatments with extended half-life
• Increased Focus on Prophylactic Treatment

Hemophilia B Market Barriers

• High Cost of Treatment
• Inconvenience and Scheduling Barriers
• Lack of Skilled Healthcare Professionals

Scope of the Hemophilia B Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hemophilia B Companies: Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure, Novo Nordisk, Freeline Therapeutics, ApcinteX, Bioverativ Therapeutics, Grifols Biologicals, Novo Nordisk A/S, Medexus Pharma, and others
• Key Hemophilia B Therapies: Marstacimab(PF-06741086), SPK-9001, Fitusiran, AMT-061, Concizumab, FLT180a, SerpinPC, rFIXFc, BeneFIX, Nonacog beta pegol, APVO101, rFIX-R, and others
• Hemophilia B Therapeutic Assessment: Hemophilia B current marketed and Hemophilia B emerging therapies
• Hemophilia B Market Dynamics: Hemophilia B market drivers and Hemophilia B market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Hemophilia B Unmet Needs, KOL’s views, Analyst’s views, Hemophilia B Market Access and Reimbursement 

To know more about Hemophilia B companies working in the treatment market, visit @ Hemophilia B Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Hemophilia B Market Report Introduction

2. Executive Summary for Hemophilia B

3. SWOT analysis of Hemophilia B

4. Hemophilia B Patient Share (%) Overview at a Glance

5. Hemophilia B Market Overview at a Glance

6. Hemophilia B Disease Background and Overview

7. Hemophilia B Epidemiology and Patient Population

8. Country-Specific Patient Population of Hemophilia B 

9. Hemophilia B Current Treatment and Medical Practices

10. Hemophilia B Unmet Needs

11. Hemophilia B Emerging Therapies

12. Hemophilia B Market Outlook

13. Country-Wise Hemophilia B Market Analysis (2019–2032)

14. Hemophilia B Market Access and Reimbursement of Therapies

15. Hemophilia B Market Drivers

16. Hemophilia B Market Barriers

17.  Hemophilia B Appendix

18. Hemophilia B Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services